Recurrent Melanoma Completed Phase 0 Trials for Resiquimod (DB06530)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01748747Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By SurgeryTreatment